Kiora Pharmaceuticals, Inc.(KPRX)Earnings, Financials & Key Ratios
KPRX•NASDAQ
$2.45
$8M mkt cap·2.8× P/E·Price updated May 7, 2026
AboutKiora Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, develops and commercializes therapies for the treatment of ophthalmic diseases in the United States. Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 1 clinical trial that acts as a photoswitch to restore vision in patients with inherited and age-related degenerative retinal diseases. The company is also developing KIO-101, an eye drop that is in Phase 2 clinical trial for the treatment of ocular presentation of rheumatoid arthritis, as well as for treating non-infectious posterior uveitis; and KIO-201, an eye drop, which is in Phase 3 clinical trial for treating patients undergoing PRK surgery for corneal wound repair after refractive surgery. The company was formerly known as Eyegate Pharmaceuticals, Inc. and changed its name to Kiora Pharmaceuticals, Inc. in November 2021. Kiora Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Salt Lake City, Utah.Show more
- Revenue$16M
- EBITDA$5M+136.1%
- Net Income$4M+128.7%
- EPS (Diluted)0.87+103.6%
- Gross Margin100%
- EBITDA Margin28.31%
- Operating Margin28.19%
- Net Margin22.47%
- ROE22.56%+115.8%
- ROIC26.24%+112.9%
- Debt/Equity0.00-87.3%
- Interest Coverage210.31+118.6%
KPRX Key Insights
Kiora Pharmaceuticals, Inc. (KPRX) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Company is almost debt free
- ✓Strong Piotroski F-Score: 8/9
- ✓FCF machine: 53.5% free cash flow margin
- ✓High quality earnings: Operating CF exceeds net income
- ✓Strong 5Y sales CAGR of 42.9%
- ✓Trading at only 0.4x book value
✗Weaknesses
- ✗Shares diluted 100.0% in last year
- ✗Trading more than 30% below 52-week high
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
KPRX Price & Volume
Kiora Pharmaceuticals, Inc. (KPRX) stock price & volume — 10-year historical chart
Loading chart...
KPRX Growth Metrics
Kiora Pharmaceuticals, Inc. (KPRX) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years42.89%
3 Years-
TTM-100%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-253.92%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-234.63%
Return on Capital
10 Years-297.9%
5 Years-58.96%
3 Years-47.65%
Last Year21.2%
KPRX Peer Comparison
Kiora Pharmaceuticals, Inc. (KPRX) competitors in Ophthalmology Therapies and Delivery — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 OCUL | 2.12B | 9.68 | -6.82 | -18.67% | -5.58% | -64.55% | 0.12 | |
 LENZ | 277.88M | 9.72 | -3.41 | -430.25% | -37.47% | 0.00 | ||
 NUVL | 7.53B | 102.40 | -17.50 | -42.78% | ||||
 ALDX | 104.08M | 1.73 | -1.84 | -87.71% | 0.22 | |||
 RCKT | 397.53M | 3.67 | -1.83 | -80.49% | 0.09 | |||
 AGIO | 1.64B | 27.53 | -3.87 | 48.03% | -6.4% | -34.11% | 0.05 | |
 REPL | 265.97M | 3.34 | -1.09 | -149.55% | 0.18 | |||
 ADVM | 96.26M | 4.36 | -0.66 | -72.22% | -189.84% | 1.30 |
Compare KPRX vs Peers
Kiora Pharmaceuticals, Inc. (KPRX) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
KPRX Income Statement
Kiora Pharmaceuticals, Inc. (KPRX) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 669.26K | 407.52K | 1.65M | 2.69M | 12.06K | 0 | 0 | 0 | 16M | 0 |
| Revenue Growth % | - | -39.11% | 305.51% | 62.54% | -99.55% | -100% | - | - | - | -100% |
| Cost of Goods Sold | 8.42M | 10.33M | 8.06M | 4.89K | 3.27M | 0 | 0 | 0 | 0 | 38.23K |
| COGS % of Revenue | 1258.49% | 2534.94% | 487.48% | 0.18% | 27138.66% | - | - | - | - | - |
| Gross Profit | -7.75M▲ 0% | -9.92M▼ 28.0% | -6.4M▲ 35.5% | 2.68M▲ 141.9% | -3.26M▼ 221.6% | 0▲ 100.0% | 0▲ 0% | 0▲ 0% | 16M▲ 0% | -38.23K▲ 0% |
| Gross Margin % | -1158.49% | -2434.94% | -387.48% | 99.82% | -27038.66% | - | - | - | 100% | - |
| Gross Profit Growth % | -616708.51% | -27.98% | 35.47% | 141.87% | -221.61% | 100% | - | - | - | - |
| Operating Expenses | 14.02M | 14.97M | 12.5M | 9.8M | 3.61M | 14.24M | 12.31M | 12.59M | 11.49M | 8.09M |
| OpEx % of Revenue | 2094.27% | 3672.66% | 756.25% | 364.67% | 29921.85% | - | - | - | 71.81% | - |
| Selling, General & Admin | 5.59M | 4.64M | 4.44M | 4.41M | 4.24M | 5.32M | 8.28M | 4.66M | 5.54M | 5.61M |
| SG&A % of Revenue | 835.78% | 1137.72% | 268.77% | 164.02% | 35200.01% | - | - | - | 34.64% | - |
| Research & Development | 8.42M | 10.33M | 8.06M | 5.39M | 3.57M | 5.35M | 3.45M | 4.03M | 4.9M | 3.72M |
| R&D % of Revenue | 1258.49% | 2534.94% | 487.48% | 200.65% | 29571.65% | - | - | - | 30.61% | - |
| Other Operating Expenses | 0 | 4.64M | 0 | 0 | -4.2M | 3.56M | 582.61K | 3.9M | 1.05M | -528.55K |
| Operating Income | -13.35M▲ 0% | -14.56M▼ 9.1% | -10.84M▲ 25.5% | -7M▲ 35.4% | -6.87M▲ 1.9% | -14.24M▼ 107.3% | -12.31M▲ 13.5% | -12.59M▼ 2.3% | 4.51M▲ 135.8% | -8.09M▲ 0% |
| Operating Margin % | -1994.27% | -3572.66% | -656.25% | -260.65% | -56960.51% | - | - | - | 28.19% | - |
| Operating Income Growth % | -99.87% | -9.08% | 25.51% | 35.44% | 1.89% | -107.25% | 13.53% | -2.25% | 135.83% | - |
| EBITDA | -13.34M | -14.54M | -10.81M | -6.79M | -6.84M | -14.19M | -12.27M | -12.54M | 4.53M | -8.07M |
| EBITDA Margin % | -1993.5% | -3567.93% | -653.92% | -252.68% | -56683.55% | - | - | - | 28.31% | - |
| EBITDA Growth % | -99.83% | -8.98% | 25.68% | 37.19% | -0.71% | -107.6% | 13.55% | -2.18% | 136.13% | -258.02% |
| D&A (Non-Cash Add-back) | 5.18K | 19.29K | 38.48K | 213.93K | 33.4K | 45.3K | 41.61K | 51.8K | 19.2K | 20.2K |
| EBIT | -13.34M | -14.56M | -10.72M | -7M | -7.51M | -13.96M | -13.69M | -12.41M | 5.68M | -9.23M |
| Net Interest Income | 3.41K | -651 | 119.32K | 107.74K | 19.15K | -5.71K | 48.29K | 162.86K | 1.23M | 1.12M |
| Interest Income | 3.68K | 564 | 120.36K | 108.07K | 23.34K | 1.14K | 56.89K | 173.99K | 1.25M | 1.14M |
| Interest Expense | 275 | 1.22K | 1.04K | 325 | 4.19K | 6.85K | 8.6K | 11.13K | 21.45K | 21.45K |
| Other Income/Expense | 3.41K | -91.7K | 119.32K | 107.74K | 19.15K | 272.48K | -1.39M | 163.32K | 1.15M | 976.36K |
| Pretax Income | -13.34M▲ 0% | -14.56M▼ 9.1% | -10.73M▲ 26.3% | -7M▲ 34.7% | -6.85M▲ 2.2% | -13.96M▼ 103.9% | -13.7M▲ 1.9% | -12.42M▲ 9.3% | 5.66M▲ 145.6% | -7.11M▲ 0% |
| Pretax Margin % | -1993.76% | -3572.82% | -649.03% | -260.66% | -56801.68% | - | - | - | 35.37% | - |
| Income Tax | 3.68K | -1.34M | 86.05K | 95.4K | 12.05K | -192.6K | -113.01K | 90.32K | 2.07M | 1.43M |
| Effective Tax Rate % | -0.03% | 9.22% | -0.8% | -1.36% | -0.18% | 1.38% | 0.83% | -0.73% | 36.49% | -20.15% |
| Net Income | -13.34M▲ 0% | -13.22M▲ 0.9% | -10.81M▲ 18.2% | -7.1M▲ 34.4% | -6.86M▲ 3.3% | -13.77M▼ 100.7% | -13.58M▲ 1.4% | -12.51M▲ 7.9% | 3.59M▲ 128.7% | -8.54M▲ 0% |
| Net Margin % | -1993.76% | -3243.52% | -654.24% | -264.21% | -56901.65% | - | - | - | 22.47% | - |
| Net Income Growth % | -58.98% | 0.94% | 18.21% | 34.36% | 3.31% | -100.69% | 1.36% | 7.88% | 128.73% | -253.92% |
| Net Income (Continuing) | -13.34M | -13.22M | -10.81M | -7.1M | -6.86M | -13.77M | -13.58M | -12.51M | 3.59M | -8.54M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -906.30▲ 0% | -556.17▲ 38.6% | -182.81▲ 67.1% | -89.24▲ 51.2% | -70.50▲ 21.0% | -68.00▲ 3.5% | -18.55▲ 72.7% | -24.25▼ 30.7% | 0.87▲ 103.6% | -1.96▲ 0% |
| EPS Growth % | -10.93% | 38.63% | 67.13% | 51.18% | 21% | 3.55% | 72.72% | -30.73% | 103.59% | -234.63% |
| EPS (Basic) | -906.30 | -556.17 | -182.81 | -89.24 | -70.50 | -68.00 | -18.55 | -24.25 | 0.93 | - |
| Diluted Shares Outstanding | 14.72K | 23.77K | 59.14K | 79.53K | 114.79K | 241.1K | 732.3K | 538.01K | 4.13M | 4.36M |
| Basic Shares Outstanding | 14.72K | 23.77K | 59.14K | 79.53K | 114.79K | 241.1K | 732.3K | 538.01K | 3.87M | 4.29M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
KPRX Balance Sheet
Kiora Pharmaceuticals, Inc. (KPRX) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 4.15M | 8.46M | 8.48M | 4.32M | 1.73M | 8.99M | 7.68M | 4.74M | 29.71M | 22.69M |
| Cash & Short-Term Investments | 3.64M | 7.81M | 8M | 3.78M | 1.19M | 7.85M | 5.96M | 2.45M | 26.79M | 19.38M |
| Cash Only | 3.64M | 7.81M | 8M | 3.78M | 1.19M | 7.85M | 5.96M | 2.45M | 3.79M | 5.51M |
| Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 23M | 13.87M |
| Accounts Receivable | 53.83K | 23.68K | 18.44K | 4.86K | 90.97K | 529.56K | 1.37M | 2.05M | 601.2K | 1.21M |
| Days Sales Outstanding | 29.36 | 21.21 | 4.07 | 0.66 | 2.75K | - | - | - | 13.71 | - |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | - | - | - | - | - | - |
| Other Current Assets | 0 | 629.59K | 455.76K | 83.93K | 0 | 0 | 343.07K | 233.38K | 270.25K | 1.45M |
| Total Non-Current Assets | 5.58M | 5.85M | 5.8M | 5.79M | 13.58M | 11.14M | 11M | 8.97M | 6.78M | 7.17M |
| Property, Plant & Equipment | 38.04K | 55.75K | 43.52K | 16.85K | 114.49K | 283.41K | 172.17K | 114.95K | 62.4K | 419.84K |
| Fixed Asset Turnover | 17.59x | 7.31x | 37.97x | 159.44x | 0.11x | - | - | - | 256.40x | 0.00x |
| Goodwill | 5.44M | 0 | 1.53M | 1.53M | 3.63M | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 5.44M | 4.16M | 4.13M | 9.73M | 10.77M | 10.74M | 8.81M | 0 | 6.69M |
| Long-Term Investments | 103.82K | 45K | 45K | 0 | 0 | 0 | 0 | 0 | 0 | 4.46K |
| Other Non-Current Assets | 100.31K | 352.13K | 76.71K | 114.4K | 102.07K | 87.96K | 82.26K | 45.03K | 6.72M | 6.91M |
| Total Assets | 9.73M▲ 0% | 14.31M▲ 47.0% | 14.28M▼ 0.2% | 10.11M▼ 29.2% | 15.3M▲ 51.3% | 20.13M▲ 31.5% | 18.68M▼ 7.2% | 13.71M▼ 26.6% | 36.48M▲ 166.1% | 29.86M▲ 0% |
| Asset Turnover | 0.07x | 0.03x | 0.12x | 0.27x | 0.00x | - | - | - | 0.44x | 0.00x |
| Asset Growth % | 2.34% | 47.01% | -0.17% | -29.19% | 51.34% | 31.53% | -7.21% | -26.59% | 166.08% | 102.06% |
| Total Current Liabilities | 7.31M | 14.83M | 3.86M | 1.41M | 1.98M | 1.61M | 3.27M | 1.63M | 6.01M | 2.58M |
| Accounts Payable | 1.41M | 706.09K | 63.65K | 210.29K | 434.76K | 160.62K | 1.01M | 206.26K | 415.59K | 241.47K |
| Days Payables Outstanding | 61.2 | 24.95 | 2.88 | 15.7K | 48.49 | - | - | - | - | 4.49K |
| Short-Term Debt | 0 | 0 | 0 | 0 | 212.28K | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Current) | 4.22M | 12.31M | 2.69M | 0 | 0 | 0 | 0 | 0 | 0 | 1.25M |
| Other Current Liabilities | 989.48K | 1.01M | 387.83K | 0 | 0 | 0 | 322.38K | 0 | 3.31M | 29.06K |
| Current Ratio | 0.57x | 0.57x | 2.19x | 3.06x | 0.87x | 5.59x | 2.35x | 2.90x | 4.94x | 4.94x |
| Quick Ratio | 0.57x | 0.57x | 2.19x | 3.06x | 0.87x | 5.59x | 2.35x | 2.90x | 4.94x | 4.94x |
| Cash Conversion Cycle | - | - | - | - | - | - | - | - | - | - |
| Total Non-Current Liabilities | 2.75M | 1.4M | 1.48M | 2.08M | 3.59M | 3.94M | 4M | 5.97M | 4.72M | 4.87M |
| Long-Term Debt | 0 | 0 | 0 | 0 | 278.19K | 0 | 0 | 0 | 0 | 0 |
| Capital Lease Obligations | 16.07K | 4.86K | 0 | 0 | 35.63K | 90.57K | 0 | 59.82K | 33.81K | 656.6K |
| Deferred Tax Liabilities | 1.53M | 183.92K | 269.97K | 365.36K | 728.93K | 802.13K | 689.12K | 779.44K | 0 | 981.38K |
| Other Non-Current Liabilities | 1.21M | 1.21M | 1.21M | 1.71M | 2.55M | 3.05M | 3.31M | 5.13M | 4.68M | 18.38M |
| Total Liabilities | 10.06M | 16.23M | 5.34M | 3.49M | 5.57M | 5.55M | 7.27M | 7.6M | 10.72M | 7.45M |
| Total Debt | 28.71K | 16.07K | 4.71K | 83.93K | 574.4K | 209.41K | 105.78K | 106.89K | 57.17K | 404.17K |
| Net Debt | -3.61M | -7.79M | -8M | -3.69M | -611.28K | -7.65M | -5.86M | -2.35M | -3.74M | -5.1M |
| Debt / Equity | - | - | 0.00x | 0.01x | 0.06x | 0.01x | 0.01x | 0.02x | 0.00x | 0.00x |
| Debt / EBITDA | - | - | - | - | - | - | - | - | 0.01x | -0.05x |
| Net Debt / EBITDA | - | - | - | - | - | - | - | - | -0.82x | -0.82x |
| Interest Coverage | -48533.99x | -11982.91x | -10427.60x | -21541.46x | -1640.91x | -2077.91x | -1431.51x | -1130.69x | 210.31x | -430.61x |
| Total Equity | -329.42K▲ 0% | -1.93M▼ 484.9% | 8.94M▲ 563.8% | 6.62M▼ 25.9% | 9.73M▲ 46.9% | 14.58M▲ 49.8% | 11.41M▼ 21.8% | 6.11M▼ 46.4% | 25.76M▲ 321.6% | 22.41M▲ 0% |
| Equity Growth % | -105.41% | -484.94% | 563.76% | -25.89% | 46.92% | 49.84% | -21.75% | -46.44% | 321.62% | 231% |
| Book Value per Share | -22.37 | -81.08 | 151.11 | 83.28 | 84.76 | 60.47 | 15.58 | 11.36 | 6.24 | 5.14 |
| Total Shareholders' Equity | -329.42K | -1.93M | 8.94M | 6.62M | 9.73M | 14.58M | 11.41M | 6.11M | 25.76M | 22.41M |
| Common Stock | 101.31K | 172.57K | 437.94K | 40.78K | 55.56K | 3.17K | 17.99K | 77.08K | 267.68K | 272.01K |
| Retained Earnings | -78.6M | -91.82M | -93.15M | -100.25M | -107.11M | -120.88M | -134.46M | -146.98M | -143.38M | -147.7M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | 120.19K | 127.47K | 134.33K | 139.47K | -802 | -86.43K | -182.74K | -182.8K | -282.16K | -243.71K |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
KPRX Cash Flow Statement
Kiora Pharmaceuticals, Inc. (KPRX) cash flow — operating, investing & free cash flow history
| Line item | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | -8.41M | -6.47M | -10.84M | -8.15M | -7.32M | -10.68M | -10.43M | -9.56M | 8.56M | 8.56M |
| Operating CF Margin % | -1257.09% | -1587.3% | -656.24% | -303.57% | -60678.07% | - | - | - | 53.49% | - |
| Operating CF Growth % | -88.67% | 23.11% | -67.65% | 24.81% | 10.26% | -45.9% | 2.32% | 8.35% | 189.56% | -347.35% |
| Net Income | -13.34M | -13.22M | -10.81M | -7.1M | -6.86M | -13.77M | -13.58M | -12.51M | 3.59M | -8.54M |
| Depreciation & Amortization | 5.18K | 19.29K | 38.48K | 213.93K | 33.4K | 45.3K | 41.61K | 51.8K | 19.2K | 47.89K |
| Stock-Based Compensation | 511K | 870.31K | 875.29K | 852.23K | 723.86K | 842.48K | 462.45K | 754.94K | 656.59K | 571.57K |
| Deferred Taxes | -511K | -1.34M | 86.05K | 0 | 12.05K | -192.6K | -113.01K | 90.32K | -288.75K | 0 |
| Other Non-Cash Items | 511K | 91.05K | 2.28M | -1.93M | -903.5K | 3.44M | 2.1M | 3.88M | 911.27K | -1.3M |
| Working Capital Changes | 4.41M | 7.11M | -1.03M | -192.54K | -321.21K | -1.04M | 668.51K | -1.82M | 3.67M | -812.84K |
| Change in Receivables | 3.24M | 32.44K | -685.74K | 0 | -18.96K | -441.2K | -872.74K | -548.11K | 1.03M | -1.8M |
| Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Payables | 712.79K | -706.04K | -642.43K | 0 | 136.7K | -310.67K | 782.46K | -808.02K | 226.12K | 244.15K |
| Cash from Investing | 149.75K | -37K | -270K | 0 | -244.44K | -157.02K | 6.38K | 0 | -22.66M | 9.56M |
| Capital Expenditures | -11K | -37K | -270K | 0 | -20.08K | -63.87K | 0 | 0 | -6.26K | 12.4K |
| CapEx % of Revenue | 1.64% | 9.08% | 16.34% | - | 166.49% | - | - | - | 0.04% | - |
| Acquisitions | 185.75K | 0 | 0 | 0 | -224.36K | -93.16K | 0 | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - | - | - | - | - |
| Other Investing | -25K | 0 | -250 | 0 | 0 | 0 | 6.38K | 0 | 0 | 0 |
| Cash from Financing | 3.5M | 10.67M | 11.3M | 3.92M | 5M | 17.58M | 8.62M | 5.97M | 15.5M | 265.36K |
| Debt Issued (Net) | -2.86K | 0 | 0 | -4.71K | 278.19K | -212.28K | 0 | 0 | 0 | 0 |
| Equity Issued (Net) | 3.77M | 10.59M | 10.11M | -2.61K | 5M | 17.75M | 5.36M | 6.97M | 15M | 265.36K |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | -2.61K | 0 | 0 | -15.63K | 0 | 0 | 0 |
| Other Financing | -267.61K | 82.17K | 1.2M | 3.93M | -280.69K | 50K | 3.26M | -1M | 499.29K | 0 |
| Net Change in Cash | -4.76M▲ 0% | 4.17M▲ 187.6% | 198.21K▼ 95.2% | -4.23M▼ 2232.9% | -2.59M▲ 38.7% | 6.67M▲ 357.4% | -1.89M▼ 128.3% | -3.55M▼ 88.5% | 1.34M▲ 137.6% | -128.18K▲ 0% |
| Free Cash Flow | -8.42M▲ 0% | -6.51M▲ 22.8% | -11.11M▼ 70.8% | -8.15M▲ 26.6% | -7.34M▲ 10.0% | -10.74M▼ 46.4% | -10.43M▲ 2.9% | -9.56M▲ 8.4% | 8.55M▲ 189.5% | -10.02M▲ 0% |
| FCF Margin % | -1258.73% | -1596.38% | -672.58% | -303.57% | -60844.56% | - | - | - | 53.46% | - |
| FCF Growth % | -88.92% | 22.78% | -70.85% | 26.64% | 10.01% | -46.37% | 2.9% | 8.35% | 189.49% | -222.52% |
| FCF per Share | -572.18 | -273.73 | -187.94 | -102.53 | -63.92 | -44.54 | -14.24 | -17.76 | 2.07 | 2.07 |
| FCF Conversion (FCF/Net Income) | 0.63x | 0.49x | 1.00x | 1.15x | 1.07x | 0.78x | 0.77x | 0.76x | 2.38x | 1.17x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
KPRX Key Ratios
Kiora Pharmaceuticals, Inc. (KPRX) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | -463.53% | - | -308.49% | -91.22% | -83.92% | -113.3% | -104.54% | -142.88% | 22.56% | -36.35% |
| Return on Invested Capital (ROIC) | - | - | -868.28% | -271.61% | -85.52% | -133.03% | -147.92% | -202.78% | 26.24% | 26.24% |
| Gross Margin | -1158.49% | -2434.94% | -387.48% | 99.82% | -27038.66% | - | - | - | 100% | - |
| Net Margin | -1993.76% | -3243.52% | -654.24% | -264.21% | -56901.65% | - | - | - | 22.47% | - |
| Debt / Equity | - | - | 0.00x | 0.01x | 0.06x | 0.01x | 0.01x | 0.02x | 0.00x | 0.00x |
| Interest Coverage | -48533.99x | -11982.91x | -10427.60x | -21541.46x | -1640.91x | -2077.91x | -1431.51x | -1130.69x | 210.31x | -430.61x |
| FCF Conversion | 0.63x | 0.49x | 1.00x | 1.15x | 1.07x | 0.78x | 0.77x | 0.76x | 2.38x | 1.17x |
| Revenue Growth | - | -39.11% | 305.51% | 62.54% | -99.55% | -100% | - | - | - | -100% |
KPRX Frequently Asked Questions
Kiora Pharmaceuticals, Inc. (KPRX) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Kiora Pharmaceuticals, Inc. (KPRX) reported $16.0M in revenue for fiscal year 2024.
Kiora Pharmaceuticals, Inc. (KPRX) grew revenue by 0.0% over the past year. Growth has been modest.
Kiora Pharmaceuticals, Inc. (KPRX) reported a net loss of $8.5M for fiscal year 2024.
Dividend & Returns
Kiora Pharmaceuticals, Inc. (KPRX) has a return on equity (ROE) of 22.6%. This is excellent, indicating efficient use of shareholder capital.
Kiora Pharmaceuticals, Inc. (KPRX) had negative free cash flow of $10.0M in fiscal year 2024, likely due to heavy capital investments.
Explore More KPRX
Kiora Pharmaceuticals, Inc. (KPRX) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates